Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate or Severe Neonatal Hypoxic-Ischemic Encephalopathy: A Report from the HEAL Trial
Developmental Neuroscience · 31.10.2023 · 46 (5) · 285-296
DOI: 10.1159/000534618 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Developmental Neuroscience, online erschienen am 31.10.2023. Verfasst von Jessica L Wisnowski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Hypoxia-Ischemia, Brain, Neuroprotective Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
Erythropoietin (Epo) is a putative neuroprotective therapy that did not improve overall outcomes in a phase 3 randomized controlled trial for neonates with moderate or severe hypoxic-ischemic encephalopathy (HIE). However, HIE is a heterogeneous disorder, and it remains to be determined whether Epo had beneficial effects on a subset of perinatal brain injuries.
Methods
This study was a secondary analysis of neuroimaging data from the High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial, which was conducted from 2016 to 2021 at 17 sites involving 23 US academic medical centers. Participants were neonates >36 weeks’ gestation undergoing therapeutic hypothermia for moderate or severe HIE who received 5 doses of study drug (Epoetin alpha 1,000 U/kg/dose) or placebo in the first week of life. Treatment assignment was stratified by trial site and severity of encephalopathy. The primary outcome was the locus, pattern, and acuity of brain injury as determined by three independent readers using a validated HIE Magnetic Resonance Imaging (MRI) scoring system.
Results
Of the 500 infants enrolled in HEAL, 470 (94%) had high quality MRI data obtained at a median of 4.9 days of age (IQR: 4.5–5.8). The incidence of injury to the deep gray nuclei, cortex, white matter, brainstem and cerebellum was similar between Epo and placebo groups. Likewise, the distribution of injury patterns was similar between groups. Among infants imaged at less than 8 days (n = 414), 94 (23%) evidenced only acute, 93 (22%) only subacute and 89 (21%) both acute and subacute injuries, with similar distribution across treatment groups.
Conclusion
Adjuvant erythropoietin did not reduce the incidence of regional brain injury. Subacute brain injury was more common than previously reported, which has key implications for the development of adjuvant neuroprotective therapies for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
- Pediatrics, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
- Biostatistics, University of Washington, Seattle, Washington, USA.
- Neurology, University of California, San Francisco, California, USA.
- Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
- Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
Förderung
- NICHD NIH HHS
- NINDS NIH HHS
Zitieren
APA
Wisnowski, J. L., Monsell, S. E., Bluml, S., Goodman, A. M., Li, Y., Comstock, B. A., Heagerty, P. J., Juul, S. E., Wu, Y. W., McKinstry, R. C., Mathur, A. M., & HEAL Consortium (2023). Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate or Severe Neonatal Hypoxic-Ischemic Encephalopathy: A Report from the HEAL Trial. Developmental Neuroscience, 46(5), 285-296. https://doi.org/10.1159/000534618
Vancouver
Wisnowski JL, Monsell SE, Bluml S, Goodman AM, Li Y, Comstock BA, et al. Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate or Severe Neonatal Hypoxic-Ischemic Encephalopathy: A Report from the HEAL Trial. Developmental Neuroscience. 2023;46(5):285-296. doi:10.1159/000534618
BibTeX
@article{Wisnowski2023,
author = {Wisnowski, Jessica L and Monsell, Sarah E and Bluml, Stefan and Goodman, Amy M and Li, Yi and Comstock, Bryan A and Heagerty, Patrick J and Juul, Sandra E and Wu, Yvonne W and McKinstry, Robert C and Mathur, Amit M and HEAL Consortium, HEAL Consortium},
title = {Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate or Severe Neonatal Hypoxic-Ischemic Encephalopathy: A Report from the HEAL Trial},
journal = {Developmental Neuroscience},
year = {2023},
volume = {46},
number = {5},
pages = {285--296},
doi = {10.1159/000534618}
}
EUVIMED